SGLT2 is a member of the sodium-glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.The growing global type-2 diabetes population promotes the growth of SGLT2 drugs.
The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors include Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Covers:
This report presents an overview of global market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
Segment by Type
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Segment by Application
Hospital
Medical Research Institute
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Invokana (Canagliflozin)
1.2.3 Jardiance (Empagliflozin)
1.2.4 Farxiga/Forxiga (Dapagliflozin)
1.2.5 Suglat (Ipragliflozin)
1.3 麻豆原创 by Application
1.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Medical Research Institute
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Estimates and Forecasts 2019-2030
2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region
2.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region (2019-2024)
2.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region (2025-2030)
2.2.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Region (2019-2030)
2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Estimates and Forecasts 2019-2030
2.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region
2.4.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region (2019-2024)
2.4.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region (2025-2030)
2.4.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Manufacturers
3.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Manufacturers (2019-2024)
3.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in 2023
3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Manufacturers
3.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Manufacturers (2019-2024)
3.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue in 2023
3.3 Global Key Players of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Product Offered and Application
3.8 Global Key Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type
4.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historical Sales by Type (2019-2024)
4.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Sales by Type (2025-2030)
4.1.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type
4.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historical Revenue by Type (2019-2024)
4.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Revenue by Type (2025-2030)
4.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Type
4.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Type (2019-2024)
4.3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price Forecast by Type (2025-2030)
5 麻豆原创 Size by Application
5.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application
5.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historical Sales by Application (2019-2024)
5.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Sales by Application (2025-2030)
5.1.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application
5.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historical Revenue by Application (2019-2024)
5.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Revenue by Application (2025-2030)
5.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Application
5.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Application (2019-2024)
5.3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Type
6.1.1 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2019-2030)
6.1.2 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2019-2030)
6.2 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Application
6.2.1 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2019-2030)
6.2.2 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2019-2030)
6.3 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country
6.3.1 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
6.3.3 US & Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Type
7.1.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2019-2030)
7.1.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2019-2030)
7.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Application
7.2.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2019-2030)
7.2.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2019-2030)
7.3 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country
7.3.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
7.3.3 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size
8.1.1 China Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (2019-2030)
8.1.2 China Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue (2019-2030)
8.2 China Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Application
8.2.1 China Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2019-2030)
8.2.2 China Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Type
9.1.1 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2019-2030)
9.1.2 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2019-2030)
9.2 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Application
9.2.1 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2019-2030)
9.2.2 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2019-2030)
9.3 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region
9.3.1 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region (2019-2030)
9.3.3 Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country
10.3.1 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Eli Lilly Recent Developments
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Company Information
11.2.2 Janssen Pharmaceuticals Overview
11.2.3 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Janssen Pharmaceuticals Recent Developments
11.3 Astellas
11.3.1 Astellas Company Information
11.3.2 Astellas Overview
11.3.3 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Astellas Recent Developments
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Information
11.4.2 Boehringer Ingelheim Overview
11.4.3 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Boehringer Ingelheim Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 AstraZeneca Recent Developments
11.6 Bristol Myers Squibb
11.6.1 Bristol Myers Squibb Company Information
11.6.2 Bristol Myers Squibb Overview
11.6.3 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Bristol Myers Squibb Recent Developments
11.7 Kotobuki Pharmaceutical
11.7.1 Kotobuki Pharmaceutical Company Information
11.7.2 Kotobuki Pharmaceutical Overview
11.7.3 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Kotobuki Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Chain Analysis
12.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Production Mode & Process
12.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales and 麻豆原创ing
12.4.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Channels
12.4.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Distributors
12.5 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Customers
13 麻豆原创 Dynamics
13.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Trends
13.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Drivers
13.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Challenges
13.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Restraints
14 Key Findings in The Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
听
听
*If Applicable.